NKTX — Nkarta, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1787400 ·
Last close
$1.25
Market Cap
$89.53M
52W High
$3.72
52W Low
$1.11
ADV30
1,463,534
Next earnings
2026-11-10

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -35,777,000 -33,326,000 308,461,000 48,354,000 92,712,000
Jun 2026 0 — -43,128,000 -40,368,000 337,645,000 24,958,000 89,907,000
Mar 2026 0 — -30,876,000 -27,832,000 372,073,000 27,356,000 86,213,000
Dec 2025 0 — -30,961,000 -27,409,000 404,209,000 39,634,000 91,884,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-92,756,000
Investing CF
$63,554,000
Financing CF
$746,000
CapEx
$-1,294,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.57
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-716,508,000
Inventory
—
Receivables
—
ST Investments
$157,806,000
EBIT TTM
$-132,251,000
Pretax Income TTM
$-117,324,000
Interest Exp TTM
—
Analysts
6

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -121,997,000 -104,084,000 404,209,000 91,884,000 312,325,000 -88,699,000
Dec 2024 0 -128,194,000 -108,790,000 501,203,000 93,227,000 407,976,000 -99,696,000
Dec 2023 0 -131,650,000 -117,501,000 378,885,000 105,600,000 273,285,000 -86,160,000
Dec 2022 0 -118,955,000 -113,837,000 472,938,000 100,731,000 372,207,000 -57,000,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-117,324,000
OpCashFlow TTM
—
Assets (Latest)
$337,645,000
Forward EPS
$-1.42

Peers — same industry

TickerNameMarket CapLastDaily %
HURA TuHURA Biosciences, Inc./NV $89.22M $1.40 —
GNLX GENELUX Corp $90.49M $2.00 —
PMVP PMV Pharmaceuticals, Inc. $92.15M $1.22 —
CPIX CUMBERLAND PHARMACEUTICALS INC $86.96M $5.80 —
RVRC Revium Rx. $86.84M $1.43 —

News headlines (Yahoo Finance, 1h cache)

Allogeneic Cell Therapy - Global Strategic Business Report 2026: Capitalize on 27.7% CAGR to Capture $2.4B by 2032 with Allogene, Gilead Sciences, Atara and Nkarta
2026-11-17 14:53 · Yahoo
Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026
2026-11-11 12:00 · Yahoo
Nkarta Reports Initial NKX019 Clinical Responses in Myositis and Systemic Sclerosis Trials
2026-11-09 13:28 · Yahoo
Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026
2026-11-06 21:01 · Yahoo
Nkarta to Participate in September Investor Conferences
2026-09-10 11:00 · Yahoo
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
2026-09-08 11:00 · Yahoo
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
2026-08-10 20:24 · Yahoo
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
2026-06-26 12:45 · Yahoo
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
2026-05-12 20:01 · Yahoo
Nkarta to Participate in Needham Virtual Healthcare Conference
2026-04-09 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.